Implantable cardiac defibrillator leads dysfunction after LVAD implantation.
implantable cardioverter defibrillator
lead parameters dysfunction
left ventricular assist device
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
25
03
2020
revised:
03
06
2020
accepted:
28
06
2020
pubmed:
7
7
2020
medline:
14
10
2021
entrez:
7
7
2020
Statut:
ppublish
Résumé
Implantable cardioverter-defibrillator (ICD) lead dysfunction has been reported after left ventricular assist device (LVAD) implantation in limited single-center studies. We aimed at describing and characterizing the incidence of ICD lead parameters dysfunction after LVAD implantation. Among the 652 patients enrolled in the ASSIST-ICD study, only patients with an ICD prior to LVAD were included (n = 401). ICD lead parameters dysfunction following LVAD implantation is defined as follows: (a) >50% decrease in sensing threshold, (b) pacing lead impedance increase/decrease by >100Ω, and (c) >50% increase in pacing threshold. One hundred twenty-two patients with an ICD prior to LVAD had available ICD interrogation reports prior and after LVAD. A total of 67 (55%) patients exhibited at least one significant lead dysfunction: 17 (15%) exhibited >50% decrease in right ventricular (RV) sensing, 51 (42%) had >100 Ω increase/decrease in RV pacing impedance, and 24 (20%) experienced >50% increase in RV pacing threshold. A total of 52 patients experienced ventricular arrhythmia during follow-up and all were successfully detected and treated by the device. All lead dysfunction could be managed conservatively. More than 50% of LVAD-recipients may experience >1 significant change in lead parameters but none had severe clinical consequences.
Sections du résumé
BACKGROUND
Implantable cardioverter-defibrillator (ICD) lead dysfunction has been reported after left ventricular assist device (LVAD) implantation in limited single-center studies. We aimed at describing and characterizing the incidence of ICD lead parameters dysfunction after LVAD implantation.
METHODS
Among the 652 patients enrolled in the ASSIST-ICD study, only patients with an ICD prior to LVAD were included (n = 401). ICD lead parameters dysfunction following LVAD implantation is defined as follows: (a) >50% decrease in sensing threshold, (b) pacing lead impedance increase/decrease by >100Ω, and (c) >50% increase in pacing threshold.
RESULTS
One hundred twenty-two patients with an ICD prior to LVAD had available ICD interrogation reports prior and after LVAD. A total of 67 (55%) patients exhibited at least one significant lead dysfunction: 17 (15%) exhibited >50% decrease in right ventricular (RV) sensing, 51 (42%) had >100 Ω increase/decrease in RV pacing impedance, and 24 (20%) experienced >50% increase in RV pacing threshold. A total of 52 patients experienced ventricular arrhythmia during follow-up and all were successfully detected and treated by the device. All lead dysfunction could be managed conservatively.
CONCLUSION
More than 50% of LVAD-recipients may experience >1 significant change in lead parameters but none had severe clinical consequences.
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1309-1317Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Foo D, Walker BD, Kuchar DL, et al. Left ventricular mechanical assist devices and cardiac device interactions: an observational case series. Pacing Clin Electrophysiol. 2009;32:879-887.
Ambardekar AV, Lowery CM, Allen LA, et al. Effect of left ventricular assist device placement on preexisting implantable cardioverter-defibrillator leads. J Card Fail. 2010;16:327-331.
Boudghène-Stambouli F, Boulé S, Goéminne C, et al. Clinical implications of left ventricular assist device implantation in patients with an implantable cardioverter-defibrillator. J Interv Card Electrophysiol. 2014;39:177-184.
Thomas IC, Cork DP, Levy A, et al. ICD lead parameters, performance, and adverse events following continuous-flow LVAD implantation. Pacing Clin Electrophysiol. 2014;37:464-472.
Hu YL, Kasirajan V, Tang DG, et al. Prospective evaluation of implantable cardioverter-defibrillator lead function during and after left ventricular assist device implantation. JACC Clin Electrophysiol. 2016;2:343-354.
Galand V, Flécher E, Auffret V, et al. Predictors and clinical impact of late ventricular arrhythmias in patients with continuous-flow left ventricular assist devices. JACC Clin Electrophysiol. 2018;4:1166-1175.
Ho G, Braun OÖ, Adler ED, Feld GK, Pretorius VG, Birgersdotter-Green U. Management of arrhythmias and cardiac implantable electronic devices in patients with left ventricular assist devices. JACC Clin Electrophysiol. 2018;4:847-859.
Tattevin P, Flécher E, Auffret V, et al. Risk factors and prognostic impact of left ventricular assist device-associated infections. Am Heart J. 2019;214:69-76.